Target intelligence / Profile preview

Protein phosphatase 2A regulatory subunit B55 alpha (B55α (also commonly abbreviated as PPP2R2A))

Target
B55α (also commonly abbreviated as PPP2R2A)
Molecular classification
Enzyme regulator, Regulatory subunit of serine/threonine-protein phosphatase complex, WD40-repeat protein
01

Overview

Protein phosphatase 2A regulatory subunit B55 alpha, encoded by the PPP2R2A gene, is a regulatory subunit of the heterotrimeric serine/threonine phosphatase PP2A. The B55 alpha subunit determines substrate specificity and cellular localization of the PP2A complex. It plays a key role in the regulation of the cell cycle, especially in entry into and exit from mitosis, by controlling the phosphorylation status of central cell cycle regulators and kinases. B55 alpha also participates in a wide array of cellular processes, including apoptosis, differentiation, DNA damage repair, mitochondrial function, and cytoskeleton organization. Dysfunction or mutations in the regulatory subunits—including B55 alpha—have been implicated in the pathogenesis of cancers and various neurodegenerative and neurodevelopmental disorders.

Other names
B55 alphaPPP2R2APR55 alphaPP2A-B55αSerine/threonine-protein phosphatase 2A 55 kDa regulatory subunit A
02

Mechanism of action

Modulation of phosphorylation status of multiple signaling proteins by dephosphorylating serine/threonine residues, thus acting as a negative regulator of kinase-driven pathways such as the AKT and MAPK cascades.

03

Biological functions

Cell cycle regulationMitosis entry and exitSignal transductionApoptosisCell differentiationDNA damage repairMitochondrial functionCytoskeleton organization
04

Disease associations

CancerNeurodegenerative diseaseNeurodevelopmental disease
05

Safety considerations

Therapeutic modulation of PP2A or its subunits may broadly impact multiple signaling pathways, raising concerns about off-target effects, cellular homeostasis, and potential toxicity due to fundamental roles in cell division and survival.
06

Interacting drugs

No specific approved drugs directly targeting B55 alpha or PPP2R2A; however, PP2A as a whole is a target for emerging small molecule modulators and inhibitors in preclinical and some clinical studies (based on broader PP2A interactions rather than this subunit alone).
07

Biomarkers

Alterations or mutations in PPP2R2A are being explored as biomarkers in some cancers and in early-onset neurodegenerative/neurodevelopmental conditions, but these are not yet routine clinical biomarkers.

Beyond the preview

Go deeper on Protein phosphatase 2A regulatory subunit B55 alpha (B55α (also commonly abbreviated as PPP2R2A)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein phosphatase 2A regulatory subunit B55 alpha (B55α (also commonly abbreviated as PPP2R2A)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call